

2024 Current Fiscal Year Report: National Cancer Institute Board of Scientific Advisors

Report Run Date: 04/26/2024 10:43:18 AM

1. Department or Agency

Department of Health and Human Services

2. Fiscal Year

2024

3. Committee or Subcommittee

National Cancer Institute Board of Scientific Advisors

3b. GSA

Committee No.

1483

4. Is this New During Fiscal Year?

No

5. Current Charter

10/08/2021 10/08/2023

6. Expected Renewal Date

7. Expected Term Date

8a. Was Terminated During Fiscal Year?

No

8b. Specific Termination Authority

8c. Actual Term Date

9. Agency Recommendation for Next Fiscal Year

Continue

10a. Legislation Req to Terminate?

Not Applicable

10b. Legislation Pending?

Not Applicable

11. Establishment Authority

Authorized by Law

12. Specific Establishment Authority

42 U.S.C. 285a-2(b)(7)

13. Effective Date

11/20/1985

14. Committee Type

Continuing

14c. Presidential?

No

15. Description of Committee

Scientific Technical Program Advisory Board

16a. Total Number of Reports

No Reports for this Fiscal Year

17a. Open

0

17b. Closed

0

17c. Partially Closed

0

Other Activities

0

17d. Total

0

Meetings and Dates

No Meetings

	Current FY	Next FY
18a(1). Personnel Pmts to Non-Federal Members	\$0.00	\$0.00
18a(2). Personnel Pmts to Federal Members	\$0.00	\$0.00
18a(3). Personnel Pmts to Federal Staff	\$0.00	\$0.00
18a(4). Personnel Pmts to Non-Member Consultants	\$0.00	\$0.00
18b(1). Travel and Per Diem to Non-Federal Members	\$0.00	\$0.00
18b(2). Travel and Per Diem to Federal Members	\$0.00	\$0.00
18b(3). Travel and Per Diem to Federal Staff	\$0.00	\$0.00
18b(4). Travel and Per Diem to Non-member Consultants	\$0.00	\$0.00
18c. Other(rents,user charges, graphics, printing, mail, etc.)	\$0.00	\$0.00
18d. Total	\$0.00	\$0.00
19. Federal Staff Support Years (FTE)	0.00	0.00

20a. How does the Committee accomplish its purpose?

The Board is composed of members who are distinguished scientists from outside the NCI and representatives from the advocacy community.

The Board provides scientific advice on a wide variety of matters concerning scientific program policy, progress and future direction of the extramural research programs, and concept review of extramural program initiatives. This includes the evaluation of NCI awarded grants, oversight of concept review of cooperative agreements and contracts initiatives and those activities which it considers meritorious and

consistent with the Institute's programs. The advisory role of the Board is scientific and does not include deliberation on matters of public policy. In FY2023, the BSA was presented reports on various topics related to cancer research in general as well as legislative matters. The Board reviewed and deliberated on request for application (RFA) concepts covering a wide variety of topics including the following: Cancer Immunoprevention Network (CIP-Net) (Re-Issue RFA/Coop. Agr.); Addressing the Needs of Cancer Survivors in Primary Care (New RFA/Coop. Agr.); Advancing Cancer Control Equity Research Through Transformative Solutions (New RFA/Coop. Agr.); Discovery and Development of Natural Products for Cancer Interception and Prevention (New RFA/Coop. Agr.); Blood and Marrow Transplant Clinical Trials Network (BMT CTN) (Re-Issue RFA/Coop. Agr.); SBIR Phase IIB Bridge Awards to Accelerate the Development of Cancer-Focused Technologies Toward Commercialization (Re-Issue RFA/Coop. Agr.); Translational Research Toward Development of Kaposi Sarcoma Herpesvirus (KSHV) Vaccine (New RFA/Coop. Agr.); Targeting Fusion Oncoproteins in Childhood Cancers (TFCC) Network (New RFA); Cooperative Human Tissue Network (CHTN) (Re-Issue RFA/Limited Comp./Coop. Agr.); Cancer Health Disparities and Minority Health (CHD-MH) SPORE Program (New RFA/Coop. Agr.); AIDS and Cancer Specimen Resource (ACSR) (Re-Issue RFA/Limited Comp./Coop. Agr.); NCI Human Tumor Atlas Network (HTAN) (Re-issue RFA/Limited Comp./Coop. Agr.); NCI National Clinical Trials Network (NCTN) (Re-Issue RFA/Limited Comp./Coop. Agr.); Innovative Molecular Analysis Technologies Program (IMAT) (Re-Issue RFA); and Pediatric Early Phase Clinical Trials Network

(PEP-CTN) (Re-Issue RFA/Coop. Agr.).

20b. How does the Committee balance its membership?

The Board consists of up to 35 members, including the Chair, appointed by the Director, NCI, from authorities knowledgeable in the fields of laboratory, clinical and biometric research, clinical cancer treatment, cancer etiology, and cancer prevention and control, with emphasis on training and experience in the various disciplines and fields related to scientific areas relevant to carcinogenesis, cancer biology and diagnosis, cancer center administration, medicine, radiological and surgical oncology, cancer chemotherapy, cancer epidemiology, cancer prevention and control, cancer education, cancer information services, community outreach, biological, chemical and physical carcinogenesis, DNA repair and effects, tumor biology and immunology, humoral and cellular immunity, hematopoiesis, cell differentiation and transformation, oncogenes and growth factors, molecular and structural biology and genetic regulation, viral oncology, vaccine development, transplantation, chemotherapy, clinical trial design, management and evaluation, pharmacology, drug development and developmental therapeutics, genetic and immunotherapies, pathology, diagnostic research and cytogenetics, biological response modifiers, imaging, nutrition, survey research, epidemiology, biostatistics, rehabilitation, psychology and behavioral medicine, public health and community oncology, quality of life, pain management, cancer detection and diagnosis, cancer treatment and restorative care, dentistry, nursing, public health, nutrition, education of health professionals, medical oncology, surgery, radiotherapy, gynecologic

oncology, pediatric oncology, pathology, and biostatistics. Geographical, gender, ethnic and racial considerations are addressed in selecting members for appointment to the Board.

20c. How frequent and relevant are the Committee Meetings?

Meetings are held not less than three times a year. The committee met three times during this reporting period. The Board met jointly with the National Cancer Advisory Board for the virtual December 2022 and in-person/hybrid June 2023 meetings. The Board also met virtually in March 2023. The Board's deliberations are an indispensable part of the review of a very large part of the Institute's extramural program, as well as concept review of request for applications (RFAs), program announcements with special receipt, referral, and review (PARs), and research and development (R&D) requests for proposals (RFP) contract initiatives in the extramural research program. According to the Board's charter, approximately three formal meetings are held each year for the review of the extramural programs and concept review of RFAs; cooperative agreements; and, research and development RFPs.

20d. Why can't the advice or information this committee provides be obtained elsewhere?

This Board is composed of recognized biomedical research authorities from outside the NIH in order to secure unbiased and objective evaluations of extramural research programs. Their recommendations are invaluable because the complex nature of the research requires a unique balance and breadth of expertise not available at NIH or from other established sources.

20e. Why is it necessary to close and/or partially closed committee meetings?

N/A

21. Remarks

Members Rotating Off/Vacancies/Members

On-Boarding: Seven members rotated off [Michael Becich, Mary Beckerle, Melissa Bondy, Leslie Robison, Robert Schreiber, Ian Thompson, and David Tuveson]. The Board currently has six vacancies, and seven members were on-boarded [Timothy Babich, Mark Doescher, Ana Maria Lopez, Lisa Newman, Raymond Osarogiagbon, Cornelia Ulrich, and Samuel Volchenbom]. This is why the Charter states 35 potential members, but this ACR lists 36. Members: The terms for Otis Brawley, Keith Flaherty, Karen Knudsen, Michelle Le Beau, W. Kimryn Rathmell, Robert Schreiber, and David Tuveson have changed due to administrative extensions. As such, their terms of service end dates are different than what was reported on the FY22 ACR. The terms for Sylvia Plevritis, David Sidransky, and Robert Vonderheide have changed due to reappointments. As such, their terms of service end dates are different than what was reported on the FY22 ACR. The terms for Michael Becich and Sylvia Plevritis are longer than the Charter allows due to their reappointment to the BSA given their specific scientific expertise and the need to assure continuity in the functions of the BSA and the deliberation of issues brought before the Board. The DFO and Committee Decision Maker positions are held by the same individual because of the assignment of responsibilities within the Institute. Reports: This committee did not produce any public reports.

Designated Federal Officer

PAULETTE S. GRAY DIRECTOR, DIVISION OF
EXTRAMURAL ACTIVITIES, NCI

Committee Members	Start	End	Occupation	Member Designation
ARE, CHANDRAKNATH	03/13/2022	06/30/2025	JERALD L. AND CAROLYN J. VARNER PROFESSOR IN SURGICAL ONCOLOGY AND GLOBAL HEALTH, ASSOCIATE DEAN FOR GRADUATE MEDICAL EDUCATION, UNIVESITY OF NEBRASKA MEDICAL CENTER	Special Government Employee (SGE) Member
BABICH, TIMOTHY	06/04/2023	06/30/2027	FOUNDER AND DIRECTOR, RUNX 1 RESEARCH PROGRAM	Special Government Employee (SGE) Member
BAKER, SUZANNE	12/19/2021	06/30/2026	ASSOCIATE DIRECTOR OF BASIC SCIENCES, ST. JUDE COMPREHENSIVE CANCER CENTER, ENDOWED CHAIR IN BRAIN TUMOR RESEARCH, ST. JUDE CHILDREN'S RESEARCH HOSPITAL	Special Government Employee (SGE) Member
BASEN-ENGQUIST, KAREN	12/05/2021	06/30/2026	PROFESSOR, DEPARTMENT OF BEHAVIORAL SCIENCE, DIVISION OF CANCER PREVENTION AND POPULATION SCIENCE, THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER	Special Government Employee (SGE) Member
BRAWLEY, OTIS	04/29/2019	12/31/2023	BLOOMBERG DISTINGUISHED PROFESSOR OF ONCOLOGY AND EPIDEMIOLOGY, SIDNEY KIMMEL COMPREHENSIVE CANCER CENTER, JOHNS HOPKINS UNIVERSITY	Special Government Employee (SGE) Member
CHAN, ANDREW	03/13/2022	06/30/2026	PROFESSOR, DEPARTMENT OF MEDICINE, HARVARD MEDICAL SCHOOL, VICE CHAIR OF CLINICAL RESEARCH, DIVISION OF GASTROENTEROLOGY, MASSACHUSETTS GENERAL HOSPITAL	Special Government Employee (SGE) Member

CHAO, NELSON	12/05/2021	06/30/2025	DONALD D. AND ELIZABETH G. COOKE DISTINGUISHED, PROFESSOR, DIVISION OF CELL THERAPY, DEPARTMENT OF MEDICINE, DUKE UNIVERSITY SCHOOL OF MEDICINE	Special Government Employee (SGE) Member
CORONADO, GLORIA	12/05/2021	06/30/2025	MITCH GREENLICK ENDOWED DISTINGUISHED INVESTIGATOR IN HEALTH DISPARITIES RESEARCH, CENTER FOR HEALTH RESEARCH, KAISER PERMANENTE NORTHWEST	Special Government Employee (SGE) Member
DOESCHER, MARK	02/26/2023	06/30/2027	PROFESSOR, DERPARTMENT OF FAMILY AND PREVENTIVE MEDICINE, COLLEGE OF MEDICINE, UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER	Special Government Employee (SGE) Member
DOUBENI, CHYKE	11/21/2021	06/30/2025	CHIEF HEALTH EQUITY OFFICER, DIRECTOR, OFFICE OF HEALTH EQUITY, DIVERSITY, AND INCLUSION, THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER	Special Government Employee (SGE) Member
EARP, HENRY	12/05/2021	06/30/2025	DIRECTOR, UNIVERSITY OF NORTH CAROLINA LINEBERGER	Special Government Employee (SGE) Member
FLAHERTY, KEITH	03/31/2019	12/31/2023	COMPREHENSIVE CANCER CENTER, UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL	Special Government Employee (SGE) Member
GRANDIS, JENNIFER	03/13/2022	06/30/2025	DIRECTOR OF CLINICAL RESEARCH, MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER	Special Government Employee (SGE) Member
			ROBERT K. WERBE DISTINGUISHED PROFESSOR IN HEAD AND NECK CANCER, UNIVERSITY OF CALIFORNIA, SAN FRANCISCO	Special Government Employee (SGE) Member

HATSUKAMI, DOROTHY	11/21/2021	06/30/2026	ASSOCIATE DIRECTOR OF CANCER PREVENTION AND CONTROL, MASONIC CANCER CENTER, PROFESSOR, DEPARTMENT OF PSYCHIATRY, UNIVERSITY OF MINNESOTA	Special Government Employee (SGE) Member
IDEKER, TREY	03/13/2022	06/30/2025	PROFESSOR, DEPARTMENT OF MEDICINE, UNIVERSITY OF CALIFORNIA, SAN DIEGO	Special Government Employee (SGE) Member
KNUDSEN, KAREN	02/03/2019	12/31/2023	CHIEF EXECUTIVE OFFICER, AMERICAN CANCER SOCIETY, INC., AMERICAN CANCER SOCIETY CANCER ACTION NETWORK	Special Government Employee (SGE) Member
LE BEAU, MICHELLE	02/03/2019	12/31/2023	ARTHUR AND MARIAN EDELSTEIN PROFESSOR OF MEDICINE AND DIRECTOR, UNIVERSITY OF CHICAGO COMPREHENSIVE CANCER CENTER, UNIVERSITY OF CHICAGO	Special Government Employee (SGE) Member
LOPEZ, ANA MARIA	02/26/2023	06/30/2027	PROFESSOR, MEDICAL ONCOLOGY AND INTEGRATIVE MEDICINE (ABOIM) AND NUTRITIONAL SCIENCES. DIRECTOR, INTEGRATIVE ONCOLOGY, ASSOCIATE DIRECTOR, DIVERSITY, EQUITY, AND INCLUSION, SIDNEY KIMMEL CANCER CENTER, NCI DESIGNATED, THOMAS JEFFERSON UNIVERSITY	Special Government Employee (SGE) Member
MUSTIAN, KAREN	03/13/2022	06/30/2026	DEAN'S DISTINGUISHED ENDOWED PROFESSOR OF ONCOLOGY AND SURGERY, DEPARTMENT OF RADIATION ONCOLOGY, JAMES P. WILMOT CANCER CENTER, UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE	Special Government Employee (SGE) Member
NEWMAN, LISA	06/04/2023	06/30/2027	PROFESSOR OF SURGERY, CHIEF DIVISION OF BREAST SURGERY, WEILL CORNELL MEDICINE	Special Government Employee (SGE) Member

OSAROGIAGBON, RAYMOND	02/26/2023	06/30/2027	ADJUNCT RESEARCH PROFESSOR, DEPARTMENT OF MEDICINE, VANDERBILT UNIVERSITY, CHIEF SCIENTIST, BAPTIST MEMORIAL HEALTH CARE CORPORATION	Special Government Employee (SGE) Member
PLEVRITIS, SYLVIA	02/05/2017	06/30/2024	PROFESSOR, DEPARTMENT OF RADIOLOGY AND BIOMEDICAL DATA SCIENCE, STANFORD UNIVERSITY SCHOOL OF MEDICINE	Special Government Employee (SGE) Member
RATHMELL, W.	03/17/2019	12/31/2023	HUGH JACKSON MORGAN PROFESSOR OF MEDICINE AND BIOCHEMISTRY, CHAIR, DEPARTMENT OF MEDICINE, PHYSICIAN-IN-CHIEF, VANDERBILT UNIVERSITY MEDICAL CENTER	Special Government Employee (SGE) Member
ROBERTSON, ERLE	12/05/2021	06/30/2026	HARRY P. SCHENK ENDOWED CHAIR PROFESSOR, VICE-CHAIR, DEPARTMENT OF OTORHINOLARYNGOLOGY, UNIVERSITY OF PENNSYLVANIA SCHOOL OF MEDICINE	Special Government Employee (SGE) Member
SIDRANSKY, DAVID	04/29/2019	12/31/2023	DIRECTOR, HEAD AND NECK CANCER RESEARCH AND PROFESSOR OF OTOLARYNGOLOGY-HEAD AND NECK SURGERY, JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE	Special Government Employee (SGE) Member
ULRICH, CORNELIA	02/26/2023	06/30/2027	CHIEF SCIENTIFIC OFFICER AND EXECUTIVE DIRECTOR, COMPREHENSIVE CANCER CENTER, HUNTSMAN CANCER INSTITUTE, UNIVERSITY OF UTAH	Special Government Employee (SGE) Member
VOLCHENBOUM, SAMUEL	02/12/2023	06/30/2027	ASSOCIATE PROFESSOR OF PEDIATRICS, DIRECTOR, PEDIATRIC CANCER DATA COMMONS. PRITZKER SCHOOL OF MEDICINE, UNIVERSITY OF CHICAGO	Special Government Employee (SGE) Member

VONDERHEIDE, ROBERT	03/17/2019	06/30/2024	JOHN H. GLICK MD ABRAMSON CANCER CENTERS, PROFESSOR, PROFESSOR OF MEDICINE, PERELMAN SCHOOL OF MEDICINE, DIRECTOR, ABRAMSON CANCER CENTER, UNIVERSITY OF PENNSYLVANIA WILLIAM A. MITCHELL PROFESSOR AND CHAIR, DEPARTMENT OF RADIATION ONCOLOGY, SIMON COMPREHENSIVE CANCER CENTER, INDIANA UNIVERSITY	Special Government Employee (SGE) Member Special Government Employee (SGE) Member
ZELLARS, RICHARD	03/13/2022	06/30/2026		

Number of Committee Members Listed: 29

Narrative Description

NIH's mission is to seek fundamental knowledge about the nature and behavior of living systems and the application of that knowledge to enhance health, lengthen life, and reduce illness and disability. NIH works toward that mission by the National Cancer Institute Board of Scientific Advisor's (BSA). The BSA is composed of distinguished scientists from outside the NCI and representatives from the advocacy community. The BSA provides scientific advice on a wide variety of matters concerning scientific program policy, reviews the progress and future direction of the extramural research programs, and concept review of extramural program initiatives. This includes the oversight of research and development, concept review of request for applications, cooperative agreements, initiatives and other programmatic activities. The advisory role of the BSA is scientific and does not include deliberation on matters of public policy. The BSA represents the scientific community's voice in the extramural science the NCI supports. As such, the Board advises the NCI leadership on the progress and future direction of the Institute's Extramural Research Program. The Board evaluates NCI extramural programs, and reviews ideas for new research opportunities and solicitations to ensure that a concept is meritorious and consistent with the Institute's mission. Additionally, the BSA believes it is important to interact with and receive feedback from the clinical, population science, and laboratory

research communities affected by NCI policies. The BSA's deliberations are an indispensable part of the review of a very large part of the Institute's extramural program.

What are the most significant program outcomes associated with this committee?

	Checked if Applies
Improvements to health or safety	<input checked="" type="checkbox"/>
Trust in government	<input type="checkbox"/>
Major policy changes	<input type="checkbox"/>
Advance in scientific research	<input checked="" type="checkbox"/>
Effective grant making	<input type="checkbox"/>
Improved service delivery	<input type="checkbox"/>
Increased customer satisfaction	<input type="checkbox"/>
Implementation of laws or regulatory requirements	<input type="checkbox"/>
Other	<input checked="" type="checkbox"/>

Outcome Comments

Based on the approval of the various RFA and RFP concepts, significant advances in cancer research could lead to new treatments, prevention and control initiatives, and behavioral modifications and cures for different cancer sites. Another outcome is the annual posting of the RFA Report.

What are the cost savings associated with this committee?

	Checked if Applies
None	<input type="checkbox"/>
Unable to Determine	<input checked="" type="checkbox"/>
Under \$100,000	<input type="checkbox"/>
\$100,000 - \$500,000	<input type="checkbox"/>
\$500,001 - \$1,000,000	<input type="checkbox"/>
\$1,000,001 - \$5,000,000	<input type="checkbox"/>
\$5,000,001 - \$10,000,000	<input type="checkbox"/>
Over \$10,000,000	<input type="checkbox"/>
Cost Savings Other	<input type="checkbox"/>

Cost Savings Comments

Meetings are held not less than three times a year. The committee met three times during this reporting period. The Board met jointly with the National Cancer Advisory Board for the virtual December 2022 and in-person/hybrid June 2023 meetings. The Board also met virtually in March 2023. Additionally, RFA and RFP concepts are reviewed annually to determine the need for reissuance based on the Board recommendations. Ad hoc Subcommittee and/or working group meetings are held to gather information. Recommendations are reported back at a full board meeting where advice is given to the Institute. The BSA supports the Institute in meeting its mission and as a result even though it can't be calculated, there are substantive savings.

What is the approximate Number of recommendations produced by this committee for the life of the committee?

516

Number of Recommendations Comments

In addition to general recommendations, specific recommendations by the committee include: 1. A motion to approve the Division of Cancer Biology's (DCB)/Division of Cancer Prevention's (DCP) new Request for Applications (RFA)/Cooperative Agreement (Coop./Agr.) entitled "Cancer Immunoprevention Network (CIP-Net)" was approved unanimously. 2. A motion to approve the Division of Cancer Control and Population Sciences' (DCCPS) new RFA Coop./Agr. entitled "Addressing the Needs of Cancer Survivors in Primary Care" was approved unanimously. 3. A motion to approve the DCCPS' new Program Announcement with special Receipt, Referral, and/or Review (PAR) entitled "The Impacts of Climate Change Across the Cancer Control Continuum" was approved unanimously. 4. A motion to approve the DCCPS' new PAR entitled "Understanding Expectancy in Cancer Symptom Management" was approved unanimously. 5. A motion to approve the DCCPS'/Center to Reduce Cancer Health Disparities' (CRCHD) RFA/Coop. Agr. entitled "Advancing Cancer Control Equity Research Through Transformative Solutions" was approved unanimously. 6. A motion to approve the DCP's RFA/Coop. Agr. entitled "Discovery and Development of Natural Products for Cancer Interception and Prevention" was approved unanimously. 7. A motion to concur on the Division of Cancer Treatment and Diagnosis' (DCTD) Re-issue RFA/Coop. Agr. entitled "Blood and Marrow Transplant Clinical Trials Network (BMT CTN)" was approved with 24 ayes, 0 nays, and 1 abstention. 8. A motion to concur on the Office of the Director's (OD) Re-issue RFA/Coop. Agr. entitled "SBIR Phase IIB Bridge Awards to Accelerate the Development of Cancer-Focused Technologies Toward Commercialization" was approved unanimously. 9. A motion to approve the OD's RFA/Cooperative Agreement (Coop. Agr.) entitled "Translational Research Toward Development of Kaposi Sarcoma Herpesvirus (KSHV) Vaccine" was approved

unanimously. 10. A motion to approve the DCTD's new RFA entitled "Targeting Fusion Oncoproteins in Childhood Cancers (TFCC) Network" was approved unanimously. 11. A motion to concur on the re-issuance of the DCTD's RFA/Limited Competition (Limited Comp.)/Coop. Agr. entitled "Cooperative Human Tissue Network (CHTN)" was approved with 21 ayes, 0 nays, and 5 abstentions. 12. A motion to approve the OD's Request for Proposals (RFP) entitled "FY 2024 NCI Small Business Innovation Research (SBIR) Contract Topics (R43)" was approved unanimously. 13. A motion to approve the DCCPS' new PAR entitled "Population Approaches to Reducing Alcohol-Related Cancer Risk (Clinical Trial Optional)" was approved unanimously. 14. A motion to approve the DCTD's new RFA/Coop. Agr. entitled "Cancer Health Disparities and Minority Health (CHD-MH) SPORE Program" was approved unanimously. 15. A motion to approve the DCP's new PAR entitled "Mechanisms That Impact Cancer Risk with Use of Incretin Mimetics" was approved unanimously. 16. A motion to approve the OD's new PAR entitled "The NCI Pathway to Independence Award for Outstanding Early-Stage Postdoctoral Researchers (K99/R00)" was approved unanimously. 17. A motion to concur on the OD's Re-issue RFA/Coop. Agr./Limited Comp. entitled "AIDS and Cancer Specimen Resource (ACSR)" was approved with 21 ayes, 0 nays, and 2 abstentions. 18. A motion to concur on 20 PAR re-issuances was approved unanimously. 19. A motion to concur on the DCB's Re-issue RFA/Coop. Agr./Limited Comp. entitled "NCI Human Tumor Atlas Network (HTAN)" was approved with 20 ayes, 1 nay, and 2 abstentions. 20. A motion to concur on the DCTD's Re-issue RFA/Coop. Agr./Limited Comp. entitled "NCI National Clinical Trials Network (NCTN)" was approved with 23 ayes, 0 nays, and 1 abstention. 21. A motion to concur on the OD's Re-issue RFA entitled "Innovative Molecular Analysis Technologies Program (IMAT)" was approved with 20 ayes, 0 nays, and 2 abstentions. 22. A motion to approve the DCCPS' new PAR entitled "Improving Care and Outcomes for Cancer Survivors from Sexual and Gender Minority (SGM) Populations (R01, Clinical Trial Optional)" was approved unanimously. 23. A motion to concur on the DCTD's Re-issue RFA/Coop. Agr. entitled "Pediatric Early Phase Clinical Trials Network (PEP-CTN)" was approved with 22 ayes, 0 nays, and 2 abstentions.

What is the approximate Percentage of these recommendations that have been or will be Fully implemented by the agency?

90%

% of Recommendations Fully Implemented Comments

The percentage of recommendations implemented as stated above was developed at the time the Annual Comprehensive Review report was prepared. Additional information is available through the RePORT (Research Portfolio Online Reporting Tool) website. RePORT provides access to reports, data, and analyses of NIH research activities that

advance the mission of the NIH, including information on NIH expenditures, strategic plans, reports on NIH funding, and reports on the organization and people involved in NIH research and research training. The RePORT website is located at <http://report.nih.gov>

What is the approximate Percentage of these recommendations that have been or will be Partially implemented by the agency?

10%

% of Recommendations Partially Implemented Comments

The percentage of recommendations implemented stated above was developed at the time the Annual Comprehensive Review report was prepared. Additional information is available through the RePORT (Research Portfolio Online Reporting Tool) website. RePORT provides access to reports, data, and analyses of NIH research activities that advance the mission of the NIH, including information on NIH expenditures, strategic plans, reports on NIH funding, and reports on the organization and people involved in NIH research and research training. The RePORT website is located at <http://report.nih.gov>.

Does the agency provide the committee with feedback regarding actions taken to implement recommendations or advice offered?

Yes ☒ No ☐ Not Applicable ☐

Agency Feedback Comments

The NCI Director's Report is presented at each Board meeting. Each NCI Division gives an update regarding progress of approved RFAs, cooperative agreements and contract concepts. Also, the Annual RFA Report is presented at each November/December Joint BSA/National Cancer Advisory Board meeting to show RFAs published and reviewed. A list of action items are assigned to individual NCI staff with specific time frames with deadlines. Information is provided to the public at each meeting. The public can view information related to the Board through the BSA official website.

What other actions has the agency taken as a result of the committee's advice or recommendation?

Checked if Applies

Reorganized Priorities	<input checked="" type="checkbox"/>
Reallocated resources	<input checked="" type="checkbox"/>
Issued new regulation	<input type="checkbox"/>
Proposed legislation	<input type="checkbox"/>
Approved grants or other payments	<input type="checkbox"/>
Other	<input type="checkbox"/>

Action Comments

Priorities are reorganized based on motions made by Board members regarding RFA and RFP concepts. Resources are allocated based on approved concepts.

Is the Committee engaged in the review of applications for grants?

No

Grant Review Comments

NA

How is access provided to the information for the Committee's documentation?

Checked if Applies

Contact DFO	<input checked="" type="checkbox"/>
Online Agency Web Site	<input checked="" type="checkbox"/>
Online Committee Web Site	<input checked="" type="checkbox"/>
Online GSA FACA Web Site	<input checked="" type="checkbox"/>
Publications	<input checked="" type="checkbox"/>
Other	<input checked="" type="checkbox"/>

Access Comments

Information on the BSA can be found at the NCI Division of Extramural Activities: Advisory Boards, Committees and Review Groups website at <http://deainfo.nci.nih.gov/advisory/bsa/bsa.htm>. Each NCI committee's charter, minutes, agenda, roster, future meeting dates, meeting PowerPoint presentations and reports is located here. Additionally, the public may view the BSA meetings (both live and on demand) via the NIH Videocast at the following website: <http://videocast.nih.gov/>.